INAVO120 Outcomes in PIK3CA-Mutated HR+/HER2-Negative Advanced Breast Cancer

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back pain after 3 months of treatment. At 14 months, she remains on inavolisib with palbociclib and fulvestrant, with controlled glucose levels and no further dose modifications. The discussion then turns to the final INAVO120 results and their implications for treatment selection, treatment duration, and quality-of-life considerations in PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer. Dr. Mouabbi reviews improvements in overall survival, progression-free survival, and objective response rate with the triplet regimen compared with palbociclib plus fulvestrant. He also highlights the longer time to chemotherapy observed with the triplet regimen and discusses how these outcomes inform conversations about the potential benefits and toxicities of treatment. The segment emphasizes proactive toxicity management as an important component of maintaining treatment while pursuing disease control, delaying chemotherapy, and supporting patients' quality of life.